What Challenges Exist in Targeting FGF/FGFR Pathways?
Despite the potential, several challenges remain:
- Resistance: Cancer cells may develop resistance to FGFR inhibitors via secondary mutations or activation of alternative pathways. - Side Effects: FGFR inhibitors can cause side effects such as hyperphosphatemia and mucositis, necessitating careful management. - Biomarker Identification: Identifying reliable biomarkers to select patients who will benefit from FGFR-targeted therapies is crucial yet challenging.
